Feyza Nur Akçin Balan

Feyza Nur Akçin Balan

Auto-generated profile, based on publicly available information

Feyza Nur Akçin Balan

Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EBElif Agüloğlu Bali
Elif Agüloğlu Bali
BCBelgin Coşkun
Belgin Coşkun
HAHalime Araz
Halime Araz
YGYakup Gezer
Yakup Gezer
ATArzu Tarakçı
Arzu Tarakçı
EAEda ALP
Eda ALP
Outpatient parenteral antimicrobial therapy (OPAT) is a well-established, cost-effective treatment modality delivered through structured, multidisciplinary

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
KBKerem Balan
Kerem Balan
FBFeyza Nur Akcin Balan
Feyza Nur Akcin Balan
Background: Topical imiquimod has been used as a skin‐directed treatment in selected patients with mycosis fungoides, but the available evidence remains limited and scattered across case reports, case series, pilot studies, retrospective cohorts, and preliminary conference data. Objective: To systematically review the published clinical evidence on topical imiquimod in mycosis fungoides, with emphasis on treatment settings, regimens, outcomes, tolerability, and durability of response. Methods: A systematic review was performed according to PRISMA principles. PubMed and Scopus were searched from database inception to April 2026 to identify publications reporting topical imiquimod use in histopathologically confirmed mycosis fungoides. Eligible publications included case reports, case series, pilot studies, retrospective cohorts, and conference abstracts with extractable imiquimod‐specific clinical outcome data. Because of marked heterogeneity in study design, disease stage, treatment schedules, follow‐up duration, and outcome reporting, the data were synthesized qualitatively. Results: Fifteen studies comprising 47 imiquimod‐treated patients or patients with MF‐related entities were included. Evidence consisted mainly of individual case reports and small case series, supplemented by pilot studies, retrospective cohorts, and one recent conference Topical imiquimod was most commonly used for localized, treatment‐refractory, or anatomically challenging lesions, including plaque‐stage, folliculotropic, and tumor‐stage mycosis fungoides. Clinical improvement, including complete or near‐complete clearance in selected reports, was described most often in localized or refractory disease. In larger observational studies, reported overall response rates were more modest, ranging from approximately 50%–60%, with complete clearance reported in 40% in one recent cohort. Local inflammatory reactions were commonly reported; however, their association with clinical improvement remains observational and cannot be interpreted as evidence of causality. Conclusions: Topical imiquimod may represent a potential individualized skin‐directed approach for selected patients with localized or treatment‐refractory mycosis fungoides. However, the current evidence remains limited, heterogeneous, predominantly low level, and subject to publication bias.

30 September 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
EBElif Agüloğlu Bali
Elif Agüloğlu Bali
YCYasemin Cakir
Yasemin Cakir
IAİrEm Akdemir
İrEm Akdemir
EAEda ALP
Eda ALP
FBFeyza Nur Akçin Balan
Feyza Nur Akçin Balan
Onder ErgonulOnder Ergonul
Onder Ergonul
Artificial intelligence (AI) is increasingly influencing healthcare, with growing relevance in infectious diseases and clinical microbiology. This review summarizes current applications of machine learning (ML), deep learning (DL), and large language models (LLMs) in these areas while critically evaluating their strengths and limitations. Although AI has shown promising performance in image analysis, molecular diagnostics, risk prediction, and clinical decision support, its routine implementation remains constrained by limited external validation, heterogeneous datasets, algorithmic bias, and challenges in generalizability and explainability. The review also discusses AI’s emerging role in scientific writing and the ethical and practical considerations associated with its clinical adoption. Overall, current evidence suggests that AI should be regarded as a complementary decision-support technology whose safe and effective integration depends on rigorous validation, high-quality data, and appropriate clinical oversight.